Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Tianjin Medical University Cancer Institute and Hospital
Shanghai Junshi Bioscience Co., Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tasly Biopharmaceuticals Co., Ltd.
National Cancer Institute, Naples
The First Affiliated Hospital of Zhengzhou University
Fujian Cancer Hospital
Jiangsu Cancer Institute & Hospital
Jiangsu Cancer Institute & Hospital
Memorial Sloan Kettering Cancer Center
Hellenic Cooperative Oncology Group
PharmaMar
Fujian Cancer Hospital
Asan Medical Center
Eisai Inc.
Taiho Pharmaceutical Co., Ltd.
Peking University
University Hospital, Ghent